User:Sonia Lee/Notebook/Gastric Cancer Immune Trials

From OpenWetWare
Jump to: navigation, search

<!-- sibboleth --><div id="lncal1" style="border:0px;"><div style="display:none;" id="id">lncal1</div><div style="display:none;" id="dtext"></div><div style="display:none;" id="page">User:Sonia Lee/Notebook/Gastric Cancer Immune Trials</div><div style="display:none;" id="fmt">yyyy/MM/dd</div><div style="display:none;" id="css">OWWNB</div><div style="display:none;" id="month"></div><div style="display:none;" id="year"></div><div style="display:none;" id="readonly">Y</div></div>

Owwnotebook icon.png <sitesearch>title=Search this Project</sitesearch>

Customize your entry pages Help.png

A brief overview of adverse events in immune-based gastric cancer trials

This was a request for a book chapter I decided not to submit. Codes covers the discussion on published evidence.

Supplementary codes (literature glean)

  • Searched strategies conducted 18th September 2015:

MEDLINE via OVID search strategy

1. Gastric Fundus/ or Vagotomy, Proximal Gastric/ or Gastric Bypass/ or Gastric Absorption/ or Gastric Outlet Obstruction/ or gastric.mp or "Esophageal and Gastric Varices"/ or Gastric Stump/ or Chief Cells, Gastric/ or Gastric Mucosa/ or Gastric Juice/ or Gastric Balloon/ or Gastric Acid/ or Gastric Emptying/ or Gastric Inhibitory Polypeptide/ or Gastric Mucins/ or "Respiratory Aspiration of Gastric Contents"/ or Gastric Lavage/ or Gastric Dilatation/ or Gastric Acidity Determination/ or Gastric Fistula/ or Parietal Cells, Gastric Antral Vascular Ectasia/
2. solid$.mp or Response Evaluation Criteria in Solid Tumors/
3. immunotherapy.mp. or Immunotherapy, Active/ or Immunotherapy/ or Sublingual Immunotherapy/ or Immunotherapy, Adoptive/
4. immun$.mp.
5. VEGF.mp or Vascular Endothelial Growth Factor/
6. Calcitonin Receptor-Like Protein/ or Nuclear Receptor Subfamily 4, Group A, Member 1/ or Interleukin-21 Receptor alpha Subunit/ or Toll-like Receptor 3/ or Genes, T-cell Receptor beta/ or Nuclear Receptor Coactivator 2/ or Receptor-Related Protein-5/ or alpha7 Nicotinic Acetylcholine Receptor/ or G-Protein-Coupled Receptor Kinase 1/ or Interleukin-13 Receptor alpha2 Subunit/ or Receptor, Parathyroid Hormone, Type 2/ or Serotonin 5-HT3 Receptor Agonists/ or Receptor, Fibroblast Growth Factor, Type 2/ or G-Protein-Coupled Receptor Kinase 3/ or Receptor, Melatonin, MT2/ or Receptor, Angiotensin, Type 1/ or Interleukin-2 Receptor beta Subunit/ or Receptor, Endothelin B/ or Bradykinin Receptor Antagonists/ or Cannabinoid Receptor Modulators/ or Adrenergic beta-1 Receptor Antagonists/ or Receptor-Like Protein Tyrosine Phosphatases, Class 2/ or Interleukin-5 Receptor alpha Subunit/ or Bradykinin B1 Receptor Antagonists/ or Receptor, Galanin, Type 2/ or NK Cell Lectin-Like Receptor Subfamily K/ or Receptor, Muscarinic M5/ or G-Protein-Coupled Receptor Kinase 4/ or Receptor-Like Protein Tyrosine Phasphatases, Class 5/ or Receptor Activity-Modifying Protein 1/ or Adrenergic beta-3 Receptor Activity-Modifying Protein 1/ or Adrenergic beta-3 Receptor Antagonists/ or Genes, T-Cell Receptor gamma/ or Low Density Lipoprotein Receptor-Related Protein-2/ or Interleukin 1 Receptor Antagonist Protein/ or GABA-A Receptor Antagonists/ or Gene Rearrangement, delta-Chain T-Cell Antigen Receptor/ or Receptor, Serotonin, 5-HT2B/ or Receptor, Galanin, Type 1/ or Protein Tyrosine Phosphatase, Non- Receptor Type 22/ or Nuclear Receptor Subfamily 4, Group A, Member 3/ or Toll-Like Receptor 7/ or Toll-Like Receptor 1/ or Receptor Protein-Tyrosine Kinases/ or Retinoid X Receptor alpha/ or Receptor, Melancortin, Type 4/ or Receptor, IGF Type 2/ or Receptor, Cannabinoid, CB2/ or Receptor, EphB1/ or Protein Tyrosine Phosphatase, Non-Receptor Type 11/ or Adrenergic beta-3 Receptor Agonists/ or Purinergic P1 Receptor Antagonists/ or Estrogen Receptor alpha/ or Receptor, EphA3/ or Aryl Hydrocarbon Receptor Nuclear Translocator/ or Vascular Endothelial Growth Factor Receptor-1/ or Protein Tyrosine Phosphatase, Non-Receptor Type 3/ or Nuclear Receptor Subfamily 1, Group F, Member 3/ or Lymphtoxin beta Receptor/ or Olfactory Receptor Neurons/ or Receptor, EphA6/ or Receptor, Platelet-Derived Growth Factor alpha/ or Receptor Activity-Modifying Protein 2/ or Adenosine A1 Receptor Agonists/ or Antidiuretic Hormone Receptor Antagonists/ or Interleukin Receptor Common gamma Subunit/ or Receptor, Adenosine A2B/ or Receptor, Adenosine A3/ or Endothelin B Receptor/ or Protein Tyrosine Phosphatases, Class 8/ or Estrogen Receptor beta/ or T-Cell Antigen Receptor Specificity/ or Oncostatin M Receptor beta Subunit/ or Receptor-CD3 Complex, Antigen, T-Cell/ or Receptor, Cholecystokinin B/ or Receptor, Galanin, Type 3/ or Androgen Receptor Antagonists/ or Nuclear Receptor Subfamily 2, Group C, Member 1/ or Dopamine D2 Receptor Antagonists/ or Bacterial Transferrin Receptor Complex/ or TNF Receptor-Associated Factor 6/ or Receptor Aggregation/ or Receptor, ErbB-2/ or Interleukin-7 Receptor alpha Subunit/ or Angiotensin II Type 2 Receptor Blockers/ or Neurokinin-1 Receptor Antagonists/ or Receptor, PAR-2/ or Receptor, TIE-1/ or Purinergic P2Y Receptor Antagonists/ or Purinergic P2X Receptor Agonists/ or Vascular Endothelial Growth Factor Receptor-3/ or Interleukin-10 Receptor alpha Subunit/ or Natural Cytoxicity Triggering Receptor 1/ or Toll-like Receptor 2/ or Receptor, Adenosine A1/ or Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor/ or Receptor, Fibroblast Growth Factor, Type 5/ or Receptor, Insulin/ or Serotonin 5-HT4 Receptor Agonists/ or Protein Tyrosine Phosphatase, Non-Receptor Type 2/ or Interleukin-12 Receptor beta 1 Subunit/ or Protein Tyrosine Phosphatase, Non-Receptor beta Subunit/ or Protein Tyrosine Phosphatase, Non-Receptor Type 13/ or G-Protein-Coupled Receptor Kinases/ or "Tumor Necrosis Factor Receptor-Associated Peptides and Proteins"/ or Interleukin-18 Receptor alpha Subunit/ or Receptor, trkC/ or Receptor-Interacting Protein Serine-Threonine Kinase 2/ or Receptor$.mp. or Receptor, Bradykinin B1/ or Amylin Receptor Agonists/ or Adenosine A2 Receptor Agonists/ or Receptor, EphB3/ or Interleukin-12 Receptor beta 2 Subunit/ or NK Cell Lecin-Like Receptor Subfamily A/ or Purinergic P2 Receptor Antagonists/ or Receptor, Notch1/ or TNF Receptor-Associated Factor 2/ or Genes, T-Cell Receptor/ or NK Cell Lectin-Like Receptor Subfamily C/ or Receptor, Ciliary Neurotrophic Factor/ or Receptor, ErbB-3/ or Receptor, Muscarinic M3/ or Receptor, EphB4/ or Receptor, Muscarinic M2/ or Toll-like Receptor 9/ or Serotonin 5-HT4 Receptor Antagonists/ or Interleukin-10 Receptor beta Subunit/ or Nuclear Receptor Subfamily 1, Group D, Member 1/ or Receptor-Like Protein Tyrosine Phosphatases, Class 7/ or Nuclear Receptor Subfamily 2, Group C, Member 2/ or Receptor, Serotonin, 5-HT1B/ or Retinoid X Receptor gamma/ or Selective Estrogen Receptor Modulators/ or Toll-Like Receptor 6/ or Receptor, EphA1/ or Receptor-Like Protein Tyrosine Phosphatases, Class 3/ or Receptor, Melanocortin, Type 2/ or Serotonin 5-HT1 Receptor Antagonists/ or Nuclear Receptor Coactivator 1/ or Receptor, Cholecystokinin A/ or Cannabinoid Receptor Agonists/ or GABA-B Receptor Agonists/ or Adrenergic alpha-1 Receptor Antagonists/ or Interleukin-11 Receptor alpha Subunit/ or B-cell Activation Factor Receptor/ or Receptor, Nerve Growth Factor/ or Leukemia Inhibitory Factor Receptor alpha Subunit/ or Genes, T-Cell Receptor delta/ or Receptor, EphA4/ or Smad Proteins, Receptor-Regulated/ or Serotonin 5-HT1 Receptor Agonists/ or Receptor, EphA7/ or Natural Cytotoxicity Triggering Receptor 3/ or Toll-like Receptor 4/ or Interleukin-4 Receptor alpha Subunit/ or Receptor, Parathyroid Hormone, Type 1/ or Adrenergic beta-1 Recetor Agonists/ or Receptor, Muscarinic M4/ or Protein Tyrosine Phosphatase, Non-Receptor Type 6/ or Receptor-Like Protein Tyrosine Phosphatases/ or Serotonin Receptor Agaonists/ or Receptor, Cannabinoid, CB1/ or Endothelin Receptor Antagonists/ or Programmed Cell Death 1 Receptor/ or Nuclear Receptor Subfamily 1, Group F, Member 2/ or Purinergic P2X Receptor Antagonists/ or Estrogen Receptor Antagonists/ or Receptor-Like Protein Tyrosine Phosphatases, Clas 4/ or Serotonin 5-HT2 Receptor Antagonists/ or Receptor Cross-Talk/ or G-Protein-Coupled Receptor Kinase 2/ or Gene Rearrangement, beta-Chain T-Cell Antigen Receptor/ or Angiotensin II Type 1 Receptor Blockers/ or Folate Receptor 2/ or Toll-like Receptor 10/ or Genes, T-Cell Receptor alpha/ or Receptor, Bradykinin B2/ or Interleukin-2 Receptor alpha Subunit/ or Bradykinin B2 Receptor Antagonists/ or Protein Tyrosine Phosphatase, Non-Receptor Type 4/ or Nuclear Receptor Kinases/ or Receptor Activity-Modifying Proteins/ or Protein Tyrosine Phosphatase, Non-Receptor Type 1/ or Cytokine Receptor Common beta Subunit/ or Interleukin-1 Receptor Accessory Protein/ or Transient Receptor Potential Channels/ or Retinoid X Receptor beta/ or Receptor, ErbB-4/ or G-Protein-Coupled Receptor Kinase 5/ or Receptor, Melanocortin, Type 1/ or Toll-Like Receptor 5/ or Purinergic P2Y Receptor Agonists/ or TNF Receptor 5/ or Puinergic P2Y Receptor Activity-Modifying Protein 3/ or Nuclear Receptor Subfamily 6, Group A, Member 1/ or Folate Receptor 1/ or Receptor, trkA/ or TNF Receptor-Associated Factor 1/ or Receptor, Melatonin, MT1/ or Adrenergic beta-2 Receptor Antagonists/ or Mineralocorticoid Receptor Antagonists/ or Serotonin 5-HT2 Receptor Agonists/ or Interleukin-15 Receptor alpha Subunit/ or Receptor, EphB2/ or Adenosine A2 Receptor Antagonists/ or Receptor Tyrosine Kinase-like Orphan Receptors/ or Purinergic P2 Receptor Agonists/ or Adrenergic alpha-2 Receptor Antagonists/ or NK Cell Lectin-Like Receptor Subfamily B/ or "Coxsackie and Adenovirus Receptor-Like Membrane Protein"/ or Adenosine A3 Receptor Agonists/ or Cannabinoid Receptor Antagonists/ or Receptor, Angiotensin, Type 2/ or Receptor, Fibroblast Growth Factor, Type 4/ or Receptor, Serotonin, 5-HT2C/
7. Tumor Marker$.mp or Biological/ or Adenocarcinoma/ or Drug Resistance.mp. Neoplasm/[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rate disease supplementary concept word, unique identifier]
8. Epidermal Growth Factor/ or EFGR.mp.
9. IGF Type 2/ or IGF Type 1/ or IGF$.mp.
10. RANK$.mp. or RANK Ligand/
11. Abdomen/ or Stomach/ or abdomen$.mp. or stoma$.mp.
12. A1B5$.mp.
13. Vascular Cell Adhesion Molecule-1/ or antigen$.mp.
14. CD/ or CD?105$.mp. or CD40 Ligand/ or CD40/ or CD?40$.mp.
15. Angiopoietin-2/ or Angiopoietin-1/ or angiopoietin$.mp. or ANG?2$.mp.
16. ErbB-2/ or Stomach Neoplasms/ or HER?2$.mp.
17. Desmosomal Cadherins/ or Cadherins/ or Cadherin$.mp.
18. Tumor Suppressor Protein p53/ or Gene$.mp. or P?53.mp.[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
19. (Adenovir$ or AD?5$).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
20. cetuxi$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
21. ramuci$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
22. figitu$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
23. denosum$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
24. CP?893.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
25. TR?105.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
26. CVX?241.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
27. pertuz$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
28. Antibod$.mp. or Monoclonal/ or Monoclon$.mp.
29. erbitux$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
30. Antineoplastic agents/ or Antineoplastic Combine Chemotherapy Protocols/ or antineoplas$.mp.
31. MLN?1202.mp.
32. Biological markers/ or C-Reactive Protein/
33. CP?752.mp.
34. CP?871.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
35. AMG?162.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
36. prolia$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
37. xgeva.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
38. "Drug-related side effects and Adverse Reactions"/ or adverse event.mp.
39. Anti-Inflammatory Agents/ or advers$.mp.
40. complication$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
41. meta-analysis.pt.
42. review.pt. and medline.tw.
43. 1 and 2
44. 3 or 4 or 28 or 30 or 32 or 39
45. 7 or 38 or 40
46. 41 or 42
47. 43 and 44 and 45 and 46
48. advers$.mp.
49. anti-inflammatory agents/ or anti?inflam$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
50. 1 or 11
51. 2 or 7
52. or/3-6
53. or/8-10
54. (or/13-37) or 12 or 49
55. or/52-54
56. 38 or 48 or 40
57. 41 or 42
58. 50 and 51 and 55 and 56 and 57


Total articles = 30

Notes


Recent changes

19 October 2017

     21:07  BME100 f2017:Group7 W0800 L4‎ (diff | hist) . . (+977). . Miguel R. Almanza Lopez (talk | contribs) (SNP Information & Primer Design)

     18:43 

BME100 f2017:Group6 W1030 L4‎‎ (4 changes | history) . . (+1,447). . [Ray Gerard Regorgo‎ (4×)]

     

18:43

(cur | prev) . . (-196). . Ray Gerard Regorgo (talk | contribs) (OUR TEAM)

     

18:42

(cur | prev) . . (-3). . Ray Gerard Regorgo (talk | contribs) (OUR TEAM)

     

17:59

(cur | prev) . . (-3). . Ray Gerard Regorgo (talk | contribs) (Research and Development)

     

16:46

(cur | prev) . . (+1,649). . Ray Gerard Regorgo (talk | contribs) (Research and Development)

     15:43  User:Julie A. Fogarty‎ (diff | hist) . . (+46). . Julie A. Fogarty (talk | contribs) (Julie A. Fogarty)

     15:33 

Rich Lab:Funding‎‎ (2 changes | history) . . (-12). . [Isabel C. Morales‎ (2×)]

     

15:33

(cur | prev) . . (+12). . Isabel C. Morales (talk | contribs)

     

14:06

(cur | prev) . . (-24). . Isabel C. Morales (talk | contribs)

     14:58 

CONJ606:Materials‎‎ (2 changes | history) . . (+1,004). . [Weinjule‎; Peteral‎]

     

14:58

(cur | prev) . . (+685). . Peteral (talk | contribs) (Week 2: Me Myself and I-dentifiers, The Key To Immortality (Persistence))

     

12:15

(cur | prev) . . (+319). . Weinjule (talk | contribs) (Papers)

     14:52 

User:Peteral‎‎ (3 changes | history) . . (+1,264). . [Peteral‎ (3×)]

     

14:52

(cur | prev) . . (+185). . Peteral (talk | contribs) (Alec's Discussion Questions)

     

13:52

(cur | prev) . . (+351). . Peteral (talk | contribs) (Alec's Discussion Questions)

     

10:53

(cur | prev) . . (+728). . Peteral (talk | contribs) (Alec's Discussion Questions)

     14:13 

BME100 f2017:Group14 W0800 L4‎‎ (9 changes | history) . . (+9). . [Shae M. Diaz‎ (9×)]

     

14:13

(cur | prev) . . (+8). . Shae M. Diaz (talk | contribs) (Protocol)

     

14:12

(cur | prev) . . (-31). . Shae M. Diaz (talk | contribs) (TEAM MEMBERS)

     

14:10

(cur | prev) . . (+31). . Shae M. Diaz (talk | contribs) (TEAM MEMBERS)

     

14:09

(cur | prev) . . (+4). . Shae M. Diaz (talk | contribs) (TEAM MEMBERS)

     

14:05

(cur | prev) . . (-1). . Shae M. Diaz (talk | contribs) (TEAM MEMBERS)

     

14:05

(cur | prev) . . (+1). . Shae M. Diaz (talk | contribs) (TEAM MEMBERS)

     

14:04

(cur | prev) . . (-1). . Shae M. Diaz (talk | contribs) (TEAM MEMBERS)

     

13:55

(cur | prev) . . (+1). . Shae M. Diaz (talk | contribs) (TEAM MEMBERS)

     

13:55

(cur | prev) . . (-3). . Shae M. Diaz (talk | contribs) (TEAM MEMBERS)

 m   14:12  Swartz‎ (diff | hist) . . (+61). . Marcus Rohovie (talk | contribs)
     14:10 (Move log) . . Marcus Rohovie (talk | contribs) moved page Swartz to Swartz:Main

     14:08 

(Upload log). .

[Thorntca‎; Shae M. Diaz‎ (3×)]

     

14:08

. . Shae M. Diaz (talk | contribs) uploaded File:100profileshae.JPG

     

14:01

. . Shae M. Diaz (talk | contribs) uploaded File:Shaediaz100.JPG

     

13:51

. . Shae M. Diaz (talk | contribs) uploaded File:BME100ShaeD.JPG

     

13:17

. . Thorntca (talk | contribs) uploaded File:2Dgel.png.jpg

     13:52 

Klenow Assembly Method: Seamless cloning‎‎ (3 changes | history) . . (+101). . [David M.D. Bailey‎ (3×)]

     

13:52

(cur | prev) . . (-5). . David M.D. Bailey (talk | contribs) (The Klenow Assembly Method (KAM) for the seamless cloning of overlapping double stranded DNA fragments: Very cheap alternative to the Gibson Assembly)

     

13:51

(cur | prev) . . (+1). . David M.D. Bailey (talk | contribs) (The Klenow Assembly Method (KAM) for the seamless cloning of overlapping double stranded DNA fragments: Very cheap alternative to the Gibson Assembly)

     

13:50

(cur | prev) . . (+105). . David M.D. Bailey (talk | contribs) (The Klenow Assembly Method (KAM) for the seamless cloning of overlapping double stranded DNA fragments: Very cheap alternative to the Gibson Assembly)

     13:22 

User:Thorntca‎‎ (8 changes | history) . . (+529). . [Thorntca‎ (8×)]

     

13:22

(cur | prev) . . (+145). . Thorntca (talk | contribs)

     

13:19

(cur | prev) . . (+17). . Thorntca (talk | contribs)

     

13:19

(cur | prev) . . (+4). . Thorntca (talk | contribs)

     

13:18

(cur | prev) . . (+30). . Thorntca (talk | contribs)

     

13:16

(cur | prev) . . (+417). . Thorntca (talk | contribs)

     

12:52

(cur | prev) . . (+12). . Thorntca (talk | contribs)

     

12:51

(cur | prev) . . (-5). . Thorntca (talk | contribs)

     

12:51

(cur | prev) . . (-91). . Thorntca (talk | contribs)

     12:27 

User:Madeline.churchill‎‎ (2 changes | history) . . (+302). . [Madeline.churchill‎ (2×)]

     

12:27

(cur | prev) . . (0). . Madeline.churchill (talk | contribs) (TZAP protein controls telomere Trimming process)

     

12:27

(cur | prev) . . (+302). . Madeline.churchill (talk | contribs) (Madeline Churchill's Discussion Page)

     09:17  BioMicroCenter:BIG meeting‎ (diff | hist) . . (+19). . George W Bell (talk | contribs) (2017-2018 academic year)
     07:06 (User creation log) . . User account Newfish (talk | contribs) was created by Yar (talk | contribs) and password was sent by email ‎

     04:10 

BioMicroCenter:BioinfoClasses‎‎ (3 changes | history) . . (+132). . [Charlie Whittaker‎ (3×)]

     

04:10

(cur | prev) . . (+9). . Charlie Whittaker (talk | contribs) (Teaching Schedule)

     

04:09

(cur | prev) . . (0). . Charlie Whittaker (talk | contribs) (Teaching Schedule)

     

04:08

(cur | prev) . . (+123). . Charlie Whittaker (talk | contribs) (Teaching Schedule)

     03:36  User:Timothee Flutre‎ (diff | hist) . . (+146). . Timothee Flutre (talk | contribs) (add contrib breedR and SO)

 m   02:27 

How to write a research paper‎‎ (2 changes | history) . . (+91). . [Formand‎ (2×)]

 m   

02:27

(cur | prev) . . (-1). . Formand (talk | contribs) (External links)

 m   

02:24

(cur | prev) . . (+92). . Formand (talk | contribs) (External links)

18 October 2017

     19:09  BME100 f2017:Group10 W0800 L4‎ (diff | hist) . . (+1). . Osvaldo J Pagan (talk | contribs)